Yes — shockwave therapy has genuine clinical evidence behind it, particularly for musculoskeletal conditions like plantar fasciitis, Achilles tendinopathy, and lateral epicondylitis, where multiple randomized controlled trials show meaningful improvements in pain and function.

Shockwave therapy works by delivering pressure waves into soft tissue, stimulating local circulation, disrupting calcific deposits, and triggering a controlled cellular repair response. The FDA cleared radial ESWT for plantar fasciitis in 2000, and a 2023 RCT found radial shockwave comparable to focused shockwave for foot function outcomes in that condition. Results depend heavily on the device delivering consistent, measurable pressure output — not all devices marketed as shockwave therapy use a true pneumatic ballistic mechanism.

  • FDA cleared radial extracorporeal shockwave therapy for plantar fasciitis in 2000.
  • Radial ESWT devices reach tissue depths of approximately 3–4 cm; focused clinical devices reach up to 12 cm.
  • Typical shockwave treatment protocols run 6–8 sessions, with each session delivering roughly 2,000 pulses.
  • Clinical radial shockwave units operate in the 1–10 bar pressure range; home devices like the Kalecope T800 cover the same range.
  • A 2023 RCT found radial and focused shockwave produced comparable foot function outcomes for plantar fasciitis.

Safety Notes

  • Active infection or open wound at treatment site: Do not apply shockwave therapy directly over broken skin, active infection, or open wounds — pressure waves can worsen tissue damage.
  • Blood clotting disorders or anticoagulant use: Shockwave therapy increases local circulation and can cause bruising; consult a physician before use if you take blood thinners or have a clotting disorder.
  • Malignancy in or near the treatment area: Do not use the Kalecope T800 or Q60 over any area with known or suspected tumor tissue — shockwave stimulates cellular activity and circulation.
  • Pregnancy: Avoid applying shockwave therapy to the abdomen or lower back during pregnancy; no safe dosage has been established for fetal exposure.
  • Growth plates in children and adolescents: Do not treat near open growth plates in skeletally immature users — pressure wave energy near developing bone carries unquantified risk.